ORSERDU™ should be administered as 345 mg orally once daily with, with dose adjustments based on adverse reactions and hepatic impairment.  

Dosage and Administration of ORSERDU™

The recommended dosage of ORSERDU™ is 345 mg taken orally once daily with food to reduce the likelihood of nausea and vomiting. Patients should take the drug at approximately the same time each day. If a dose is missed for more than six hours or if vomiting occurs, skip the missed dose and take the next dose at the usual time. Dose reductions may be required if adverse reactions occur. In patients with moderate hepatic impairment (Child-Pugh B), the dosage should be reduced to 258 mg once daily. Severe hepatic impairment is a contraindication for ORSERDU™ use.

Elacestrant(Orserdu)
ORSERDU™ is indicated for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
RELATED ARTICLES
/ 0
0 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved